Celgene Corporation (NASDAQ (GS): CELG)
Overview
A terror from the past has provided hope in the present. Celgene's flagship products Thalomid and Revlimid are versions of the infamous thalidomide, the morning sickness remedy pulled from shelves in the 1960s after it was linked to birth defects. Both drugs are approved in the US and Europe as a treatment for multiple myeloma (bone marrow cancer). Revlimid also is used to treat a malignant blood disease called MDS. Celgene sells each drug under strict risk management plans that ensure they are safely administered. The firm has other drugs in development that combat inflammatory diseases and cancer. In 2008 Celgene acquired fellow Thalidomide resurrector Pharmion for $2.9 billion.
Sample OverviewKey Numbers from Hoover's UK
Key financials for Celgene Corporation (NASDAQ (GS): CELG)
| Company Type | Public (NASDAQ (GS): CELG) |
|---|---|
| Fiscal Year-End | December |
| 2008 Sales (mil.) | £1,557.2 |
| 1-Year Sales Growth | 60.4% |
| 2008 Net Income (mil.) | (£1,059.1) |
| 2008 Employees | 2,441 |
| 1-Year Employee Growth | 44.9% |
Key People from Hoover's UK
Key people and executives for Celgene Corporation (NASDAQ (GS): CELG)
| Chairman and CEO | Sol J. Barer (Subscribers see complete biographies -- view sample)
Connect to this executive |
|---|---|
| President, COO, and Director | Robert J. (Bob) Hugin Connect to this executive |
| SVP and CFO | David W. Gryska Connect to this executive |
Top Competitors from Hoover's UK
Top competitors of Celgene Corporation (NASDAQ (GS): CELG)
There are 18 competitors for Celgene; see more.Industry Information from Hoover's UK
First Research Industry Profiles Extensive Industry Intelligence
Hoover's Industries
More Industry InformationSubsidiaries/Affiliates Covered By Hoover's UK
Subsidiaries/affiliates of Celgene Corporation (NASDAQ (GS): CELG)
Rankings from Hoover's UK
See how Celgene Corporation (NASDAQ (GS): CELG) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones
- S&P 500
- #230 in FT Global 500
